Cytotoxic and Apoptogenic Effects of Cyanidin-3-Glucoside on the Glioblastoma Cell Line

World Neurosurgery

Volumn 108, Issue , 2017, Pages 94-100

  Hosseini, Masoumeh Mansoubi ^a   Karimi, Aliasghar ^d   Behroozaghdam, Mitra ^b   Javidi, Mohammad Amin ^c   Ghiasvand, Saeedeh ^e   Bereimipour, Ahmad ^b   Aryan, Hoda ^b   Nassiri, Farbod ^b   Jangholi, Ehsan ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MALAYER UNIVERSITY   (Iran)

Author keywords

Apoptosis; Cisplatin; Cyanidin 3 glucoside; Glioblastoma; U87 cells

Indexed keywords

CISPLATIN; CYANIDIN 3 GLUCOSIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; ANTHOCYANIN; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; CYANIDIN 3-O-GLUCOSIDE; GLUCOSIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOBLASTOMA MULTIFORME CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOCYTOCHEMISTRY; MTT ASSAY; PROPIDIUM IODIDE ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; U87 CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TIME FACTOR; TUMOR CELL LINE;

ANTHOCYANINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GLIOBLASTOMA; GLUCOSIDES; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85029615301     PISSN: 18788750     EISSN: 18788769     Source Type: Journal    
DOI: 10.1016/j.wneu.2017.08.133     Document Type: Article

References (40)

1. Ohgaki, H., Kleihues, P., Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170 (2007), 1445–1453.
2. Ellis, H.P., Greenslade, M., Powell, B., Spiteri, I., Sottoriva, A., Kurian, K.M., Current challenges in glioblastoma: intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front Oncol, 5, 2015, 251.
3. Grana, X., Reddy, E.P., Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11 (1995), 211–220.
4. Colditz, G.A., Branch, L.G., Lipnick, R.J., Willett, W., Rosner, B., Posner, B., et al. Increased green and yellow vegetable intake and lowered cancer deaths in an elderly population. Am J Clin Nutr 41 (1985), 32–36.
5. Bagchi, D., Sen, C., Bagchi, M., Atalay, M., Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. Biochemistry (Mosc) 69 (2004), 75–80.
6. Hyun, J.W., Chung, H.S., Cyanidin and malvidin from Oryza sativa cv. Heugjinjubyeo mediate cytotoxicity against human monocytic leukemia cells by arrest of G2/M phase and induction of apoptosis. J Agric Food Chem 52 (2004), 2213–2217.
7. Mirmalek, S., Jangholi, E., Jafari, M., Yadollah-Damavandi, S., Javidi, M., Parsa, Y., et al. Comparison of in vitro cytotoxicity and apoptogenic activity of magnesium chloride and cisplatin as conventional chemotherapeutic agents in the MCF-7 cell line. Asian Pac J Cancer Prev 17 (2016), 131–134.
8. Katsuzaki, H., Hibasami, H., Ohwaki, S., Ishikawa, K., Imai, K., Date, K., et al. Cyanidin-3-O-β-D-glucoside isolated from skin of black Glycine max and other anthocyanins isolated from skin of red grape induce apoptosis in human lymphoid leukemia Molt 4B cells. Oncol Rep 10 (2003), 297–300.
9. Katsube, N., Iwashita, K., Tsushida, T., Yamaki, K., Kobori, M., Induction of apoptosis in cancer cells by bilberry (Vaccinium myrtillus) and the anthocyanins. J Agric Food Chem 51 (2003), 68–75.
10. Liu, M., Li, X.Q., Weber, C., Lee, C.Y., Brown, J., Liu, R.H., Antioxidant and antiproliferative activities of raspberries. J Agric Food Chem 50 (2002), 2926–2930.
11. Chen, P.N., Chu, S.C., Chiou, H.L., Chiang, C.L., Yang, S.F., Hsieh, Y.S., Cyanidin 3-glucoside and peonidin 3-glucoside inhibit tumor cell growth and induce apoptosis in vitro and suppress tumor growth in vivo. Nutr Cancer 53 (2005), 232–243.
12. Ding, M., Feng, R., Wang, S.Y., Bowman, L., Lu, Y., Qian, Y., et al. Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. J Biol Chem 281 (2006), 17359–17368.
13. Shih, P.H., Yeh, C.T., Yen, G.C., Effects of anthocyanidin on the inhibition of proliferation and induction of apoptosis in human gastric adenocarcinoma cells. Food Chem Toxicol 43 (2005), 1557–1566.
14. Xu, M., Bower, K.A., Wang, S., Frank, J.A., Chen, G., Ding, M., et al. Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2. Mol Cancer, 9, 2010, 285.
15. Hartwell, L.H., Kastan, M.B., Cell cycle control and cancer. Science, 266, 1994, 1821.
16. Basu, A., Haldar, S., Apoptosis, antiapoptosis and bcl-2. EOS Rivista di Immunologia ed Immunofarmacologia 16 (1996), 41–47.
17. Hengartner, M.O., Programmed cell death in invertebrates. Curr Opin Genet Dev 6 (1996), 34–38.
18. White, E., Life, death, and the pursuit of apoptosis. Genes Dev 10 (1996), 1–15.
19. Yuan, J., Transducing signals of life and death. Curr Opin Cell Biol 9 (1997), 247–251.
20. Cleary, M.L., Smith, S.D., Sklar, J., Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t (14; 18) translocation. Cell 47 (1986), 19–28.
21. Tsujimoto, Y., Finger, L.R., Yunis, J., Nowell, P.C., Croce, C.M., Cloning of the chromosome breakpoint of neoplastic B cells with the t (14; 18) chromosome translocation. Science 226 (1984), 1097–1100.
22. Tsujimoto, Y., Cossman, J., Jaffe, E., Croce, C.M., Involvement of the bcl-2 gene in human follicular lymphoma. Science 228 (1985), 1440–1444.
23. Bakshi, A., Jensen, J.P., Goldman, P., Wright, J.J., McBride, O.W., Epstein, A.L., et al. Cloning the chromosomal breakpoint of t (14: 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41 (1985), 899–906.
24. Kitada, S., Krajewski, S., Miyashita, T., Krajewska, M., Reed, J.C., Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 12 (1996), 187–192.
25. Thomas, A., El Rouby, S., Reed, J.C., Krajewski, S., Silber, R., Potmesil, M., et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12 (1996), 1055–1062.
26. Meikrantz, W., Schlegel, R., Apoptosis and the cell cycle. J Cell Biochem 58 (1995), 160–174.
27. Merritt, A.J., Allen, T.D., Potten, C.S., Hickman, J.A., Apoptosis in small intestinal epithelia from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene 14 (1997), 2759–2766.
28. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V.-M., Niskanen, E., et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55 (1995), 4471–4478.
29. Leek, R.D., Kaklamanis, L., Pezzella, F.A., Gatter, K.C., Harris, A.L., bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer, 69, 1994, 135.
30. Basu, A., Haldar, S., The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 4 (1998), 1099–1109.
31. Mrugala, M.M., Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med 15 (2013), 221–230.
32. Baumert, B.G., Hegi, M.E., van den Bent, M.J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17 (2016), 1521–1532.
33. Hicks, M.J., Funato, K., Wang, L., Aronowitz, E., Dyke, J.P., Ballon, D.J., et al. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther 22 (2015), 1–8.
34. Lu-Emerson, C., Duda, D.G., Emblem, K.E., Taylor, J.W., Gerstner, E.R., Loeffler, J.S., et al. Lessons from anti–vascular endothelial growth factor and anti–vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33 (2015), 1197–1213.
35. van Tellingen, O., Yetkin-Arik, B., de Gooijer, M.C., Wesseling, P., Wurdinger, T., de Vries, H.E., Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 19 (2015), 1–12.
36. Lohcharoenkal, W., Wang, L., Chen, Y.C., Rojanasakul, Y., Protein nanoparticles as drug delivery carriers for cancer therapy. Biomed Res Int, 2014, 2014, 180549.
37. Wu, M., Fan, Y., Lv, S., Xiao, B., Ye, M., Zhu, X., Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv 23 (2016), 2720–2725.
38. Song, S., Mao, G., Du, J., Zhu, X., Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv 23 (2016), 1404–1408.
39. Alexis, F., Rhee, J.W., Richie, J.P., Radovic-Moreno, A.F., Langer, R., Farokhzad, O.C., New frontiers in nanotechnology for cancer treatment. Urol Oncol 26 (2008), 74–85.
40. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2 (2007), 751–760.